AKTSAktis Oncology, Inc.

$26.58

$15.1952 weeks$31.15

Price

$26.58

1M+11%1Y-

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Top tier

9/10

Value-

Quality42

Momentum97

Growth-

Strongest Momentum, weakest Quality · ranked vs Healthcare peers. The five questions below judge the company on its own terms.

What they do

We are a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The field of targeted radiopharmaceuticals is currently led by two marketed products that illustrated transformative survival outcomes and quality of life benefits can be conferred by delivering radioisotopes to solid tumors.

In the company’s own words · 10-K filed Mar 30, 2026 · SEC EDGAR

P/E (TTM)-

Market Cap$1.33B

1Y Return-

5Y Return-

Aktis Oncology, Inc. (AKTS) reported revenue of $3.4M in Q2 2026 (quarter ended June 30, 2026), up 134% from the same quarter a year earlier. That came with net loss of $24M.

Raw charts

6 series · TTM

As reported to the SEC, without any scoring.

Biotechnology

Ranks #52 of 145 by Smart Score

Bicara Therapeutics Inc.